SARMs and CBD: Navigating Regulatory Gaps in UK's Food Industry - Unusual products blur the lines between food and medicine, prompting questions about effective regulation.
Professor Trevor Jones, Chair at the European Medicinal Cannabis Association, speaks to Nishat about their plans for EU patient access to medicinal cannabis.
David Shurtleff, PhD, Deputy Director at the National Center for Complementary and Integrative Health, National Institutes of Health, discusses new funding opportunities for cannabinoid research.
Here, we learn how about a different kind of green crop that grows in Ireland and the journey of that from seed to shelf as part of the Greenheart CBD story.
In the last six months GreenLight Medicines has successfully out-licenced leads from its research, branching out internationally and attracting major investors.
In this interview, David Engel from Full Moon Investments in the U.S., charts the firm’s successful targeted investment strategy – informed by industry-leading experience and expertise – including comments on the CBD hemp and medical cannabis space.
Elixinol has launched a new UK range of blended, full-spectrum CBD capsules using six original combinations developed to support good health and wellbeing.
In this final article of a series of five, Oxford Cannabinoid Technologies will discuss their expertise on the use of cannabinoids in medicine when it comes to treating COVID-19.
Here, OilsBySimpson explains the findings of a new study on 400 patients prescribed cannabidiol (CBD). The results show promise for pain, anxiety, and depression.
Christian Hendriksen, VP of International Expansion at Mile High Labs, illustrates how they are continuing compliance with the novel food application to ensure safe and effective cannabinoids can be available to all.
Here, OilsBySimpson Founder Kevin William Simpson, explains what current research shows about CBD’s effect on epilepsy and its applications as a treatment.
